Autonomix Medical Enters into $2.6 Million Warrant Inducement Priced At-the-Market Under Nasdaq Rules

THE WOODLANDS, TX, July 13, 2026 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it has entered into a warrant inducement agreement with an investor (“Investor”) for the immediate exercise of certain outstanding warrants that the Company issued on November 19, 2025 (the “November 2025 Warrants”). Pursuant to a warrant inducement agreement, the Investor has agreed to exercise the outstanding November 2025 Warrants to purchase an aggregate of 428,731 shares of the Company’s common stock at the amended and reduced exercise price of $6.00. The resale of the shares of common stock issuable upon exercise of the November 2025 Warrants has been registered pursuant to an effective registration statement on Form S-3 (File No. 333- 291825). The gross proceeds from the exercise of the warrants are expected to be approximately $2.6 million, prior to deducting financial advisory fees and estimated offering expenses.